Infinity Pharmaceuticals Pulls Plug on Treatment for Prostate Cancer

Xconomy Boston — 

Infinity Pharmaceuticals, the Cambridge, MA-based developer of cancer drugs, said today it has halted enrollment in a mid-stage study of IPI-504 for patients with prostate cancer, after it didn’t see evidence the drug was working. The treatment, being developed in partnership with AstraZeneca, will continue to be tested against non-small cell lung cancer and gastrointestinal stromal tumors, a deadly stomach cancer. A study presented in May at the American Society of Clinical Oncology was so promising against gastrointestinal stromal tumors that the FDA has agreed to allow Infinity to skip the second of three phases of study usually required.